en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Wiki › Research And Regulatory Context — Deep Dive

Research And Regulatory Context — Deep Dive

By Editorial Desk · published 2026-05-03 · last reviewed 2026-05-21 · Wiki

Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineMajor agencies have not authorized it for therapeutic use.
Anti-doping statusProhibited in sportListed among peptide hormones and related substances.
Primary research areaMetabolic and body-composition effectsStudies often examine fat mass or lipid markers.
Human evidenceLimited and mixedPublic data do not establish clinical efficacy.
Analytical detectionLC-MS and immunoassaysMethods vary in sensitivity and validation.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Related pages on this site

Measurement and Storage Practices

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Background from the literature

=== Czech === Traditionally, the word nejneobhospodařovávatelnějšími ("of the least cultivable", 28 letters) is considered as the longest Czech word, but there are some longer artificial words. Most of them are compound adjectives in dative, instrumental or other grammatical case and derived from the iterative or frequentative verbal form or the ability adjective form (like "-able").

== Photocatalytic-based Proximity Labeling == A new frontier in the field of proximity labeling exploits the utility of photocatalysis to achieve high spatial and temporal resolution of proximal protein microenvironments. This photocatalytic technology leverages the photonic energy of iridium-based photocatalysts to activate diazirine probes that can tag proximal proteins within a tight radius of about four nanometers. This technology was developed by the Merck Exploratory Science Center in collaboration with researchers at Princeton University. This technology was spun out of the Merck Exploratory Science Center into InduPro, a biotech company founded in 2022 by three Merck scientists, including Rob Oslund and Niyi Fadeyi, who co-invented the mapping technology.

==== Enamel hypoplasia ==== Enamel hypoplasia refers to transverse furrows or pits that form in the enamel surface of teeth when the normal process of tooth growth stops, leaving a deficit. Enamel hypoplasias generally form due to disease and/or poor nutrition. Linear furrows are commonly referred to as linear enamel hypoplasias (LEHs); LEHs can range in size from microscopic to visible to the naked eye. By examining the spacing of perikymata grooves (horizontal growth lines), the duration of the stressor can be estimated, although Mays argued that the width of the hypoplasia bears only an indirect relationship to the duration of the stressor. Studies of dental enamel hypoplasia are used to study child health. Unlike bone, teeth are not remodeled, so intact enamel can provide a more reliable indicator of past health events. Dental hypoplasias provide an indicator of health status during the time in childhood when the enamel of the tooth crown is forming. The presence, frequency, and severity of enamel hypoplasia (EH) offer valuable information about general health conditions and the occurrence of disease or malnutrition. Elevated rates of EH are often interpreted as evidence of widespread physiological stress, such as famine, infectious disease outbreaks, or prolonged nutritional deficiencies. By comparing the prevalence of dental stress indicators across various groups such as different social classes, geographic regions, or time periods bioarcheologists can also infer disparities in living conditions, access to resources, and overall health.

Sources: en.wikipedia.org

Reference notes

Antidotes can be employed to either mop up hazardous metabolites or change them into less toxic forms once they have developed. Hepatic glutathione stores are replenished by N-acetyl cysteine, and this process is what leads to the conjugation of the poisonous metabolite N-acetyl P-benzoquinone imine (NAPQI). Receptor antagonist Receptor Dose–response relationship Pharmacodynamics Antidotes

==== Transistors ==== Bismuth-based materials have been claimed to enable smaller, faster, and more energy-efficient transistors than traditional silicon. Bismuth offers a small bandgap and high electron mobility. It has topological insulator states, conducting along its surface/edges while still insulating internally. Two-dimensional semiconductor (2D) materials can be produced from it, enabling thinner and higher-performance devices. Such 2D bismuth materials support subnanometer channel lengths, surpassing silicon's practical limits. However, bismuth's anisotropic heat transport can complicate chip design. Bismuth telluride (Bi2Te3) has been investigated for use in thermoelectric transistors that use temperature gradients (e.g., via laser illumination) to generate electricity, yielding 0.7093 μW in experimental setups. They operate by leveraging the Seebeck effect, using a temperature difference to drive charge carrier movement. Bismuth oxyselenides (Bi2O2Se and Bi2SeO5) have been investigated for use in field-effect transistors (FETs). These 2D materials exhibit high electron mobility (e.g., 10–15 cm2/(V·s)) and stability in air. One study reported that these materials enabled transistors that were 40% faster and 10% more efficient than Intel's 3 nm chips. Bismuth can reduce contact resistance when paired with 2D semiconductors such as MoS2. This eliminates the Schottky barrier—a common efficiency issue in metal-semiconductor interfaces.

Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market. Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an EC50 of 3.0 μM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model. Inhibits HUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.

==== On Natural Amino Acids ==== Trp arylation Multiple methods have been reported to achieve tryptophan C–H arylation, where diverse electrophiles such as aryl halides and aryl boronic acids (an example shown below) have been used to transfer the aryl groups. However, current tryptophan C–H arylation reaction conditions remain relatively harsh, requiring organic solvents, low pH and/or high temperatures.

Sources: en.wikipedia.org

Reference notes

=== Follicular phase === GnSAF prevents a pre-ovulatory surge in LH during this time, allowing sufficient time for the dominant follicle to mature before ovulation. At the start of the follicular phase, high serum FSH concentrations stimulate the development and proliferation of the granulosa cells of the small antral follicles, resulting in a steady increase in GnSAF biosynthesis. The relatively high GnSAF bioactivity dampens the response of the pituitary gland to GnRH by antagonising the sensitising effects of estradiol on the pituitary gland. The GnRH pulse, in the presence of GnSAF, is not frequent or potent enough to stimulate LH secretion from the anterior pituitary above basal levels.

The Campaign for Safe Cosmetics has also highlighted concerns. Numerous studies have revealed that hydroquinone, if taken orally, can cause exogenous ochronosis, a disfiguring disease in which blue-black pigments are deposited onto the skin; however, skin preparations containing the ingredient are administered topically. The FDA had classified hydroquinone in 1982 as a safe product—generally recognized as safe and effective (GRASE). Additional studies under the National Toxicology Program (NTP) were suggested to determine whether there is a risk to humans from the use of hydroquinone. NTP evaluation showed some evidence of long-term carcinogenic and genotoxic effects. While hydroquinone remains widely prescribed for treatment of hyperpigmentation, questions raised about its safety profile by regulatory agencies in the EU, Japan, and the USA encourage the search for other agents with comparable efficacy. Several such agents are already available or under research, including azelaic acid, kojic acid, retinoids, cysteamine, topical steroids, glycolic acid, and other substances. One of these, 4-butylresorcinol, has been proven to be more effective at treating melanin-related skin disorders by a wide margin, as well as safe enough to be made available over the counter. In the anthraquinone process, substituted hydroquinones, typically anthrahydroquinone, are used to produce hydrogen peroxide, which forms spontaneously on reaction with oxygen. The type of substituted hydroquinone is selected depending on reactivity and recyclability.

My grandfather came to this country circa 1895 from Montella, Italy. Around 1910, he started his grocery store, called Dominic Conti's Grocery Store, on Mill Street in Paterson, New Jersey where he was selling the traditional Italian sandwiches. His sandwiches were made from a recipe he brought with him from Italy, which consisted of a long crust roll, filled with cold cuts, topped with lettuce, tomatoes, peppers, onions, oil, vinegar, Italian herbs and spices, salt, and pepper. The sandwich started with a layer of cheese and ended with a layer of cheese (this was so the bread wouldn't get soggy).

In 1974, Detroit elected its first black mayor, Coleman Young. Coleman Young aimed to create a racially diverse cabinet and police force, half black and half white members, leading to a new face representing Detroit on the global stage. Most important, however, was the population decline's negative effect on Detroit's economy. Following the population decline, Detroit's tax revenue significantly decreased. The government was receiving less revenue from taxpayers residing in the city which led to more foreclosures and overall unemployment, eventually culminating in the bankruptcy of 2013. Detroit's population continues to decline today, impacting its majority poor, black demographic the hardest. Because urban renewal, highway construction, and discriminatory loan policies contributed to white flight to the suburbs, the remaining poor, black city population endured radical disinvestment and a lack of public services such as dilapidated schools, a lack of safety, blighted properties, and waste, contributing the reality of families living in the city today. Furthermore, Detroit has the highest property tax of any major U.S. city, making it difficult for many families to afford to live there. White flight does appear to be reversing starting in the 1990s, with affluent white families returning to the city and gentrifying areas of urban decay and blight. However, this has caused many physical and cultural displacement issues, disproportionately impacting marginalized minority communities.

In consultation with a physician, usage of herbal remedies should be clarified, as some herbal remedies have the potential to cause adverse drug interactions when used in combination with various prescription and over-the-counter pharmaceuticals, just as a customer should inform a herbalist of their consumption of actual prescription and other medication. For example, dangerously low blood pressure may result from the combination of a herbal remedy that lowers blood pressure together with prescription medicine that has the same effect. Some herbs may amplify the effects of anticoagulants. Certain herbs as well as common fruit interfere with cytochrome P450, an enzyme critical to much drug metabolism. In a 2018 study, the FDA identified active pharmaceutical additives in over 700 analyzed dietary supplements sold as "herbal", "natural" or "traditional". The undisclosed additives included "unapproved antidepressants and designer steroids", as well as prescription drugs, such as sildenafil or sibutramine.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.

Why is AOD-9604 banned in sports?

It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.

What do human studies show?

Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network